A study to evaluate the efficacy of BCG vaccination in the treatment of multiple warts

BCG immunotherapy in recurrent multiple verrucae vulgaris.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/08/004834

Enrollment

Registered

2014-08-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- MULTIPLE WARTS

Interventions

Intervention1: BCG vaccine: 0.1 ml BCG vaccine intralesional in the target wart at an interval of 3 weeks till complete clearance of wart or maximum 3 treatments without response. Control Intervention

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient should have multiple warts (more than 2). 2.The age of the patient more than 17 years. 3.No concurrent systemic or topical treatment of warts

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Number of Participants with Clinical Resolution of Injected wart. When the participant completes the protocol, clinical resolution of the injected wart will be determined by the overall percentage of resolution from the initial visit. Complete response- 100% disappearance of warts. Partial response- 25-99% reduction in size. No response- 0-25% reduction in size.Timepoint: 5months	—

Secondary

Measure	Time frame
Number of Participants with Clinical Resolution of Non-injected Wart. When the participant completes the protocol, clinical resolution of anatomically distant, non-injected wart will be determined by the overall percentage of resolution from the initial visit.Timepoint: 5months.	—

Countries

India

Contacts

Public ContactAVTAR KISHAN JAISINGHANI

PEOPLES HOSPITAL, BHOPAL

colnelms@yahoo.com09591711114

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026